Levosulpiride
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C15H23N3O4S |
Molar mass | 341.43 g·mol−1 |
| |
(what is this?) (verify) |
Levosulpiride is a substituted benzamide antipsychotic,[1] reported to be a selective antagonist of dopamine D2 receptor activity[2] on both central and peripheral levels. It is an atypical neuroleptic and a prokinetic agent.[2] Levosulpiride is also claimed to have mood elevating properties.
Chemically, it is the (S)-(−)-enantiomer of sulpiride.
Uses
Levosulpiride is used in the treatment of:
- psychoses
- particularly negative symptoms of schizophrenia
- anxiety disorders
- dysthymia
- vertigo
- dyspepsia
- irritable bowel syndrome
- premature ejaculation.
Levosulpiride is not currently licensed for treatment of premature ejaculation in the UK or other European countries.[3]
Side effect
Side effects include amenorrhea, gynecomastia, galactorrhea, changes in libido, and neuroleptic malignant syndrome.[4] In the U.S., as of 2013 only one case of adverse reaction to Levosulpiride had been recorded on the FDA Adverse Event Reporting System Database.[5] A case of rapid onset resistant dystonia caused by low dose levosulpiride was reported in India.[6]
Mechanism of action
In contrast to most other neuroleptics which block both dopamine D1 and D2 receptors, sulpiride is more selective and acts primarily as a dopamine D2 antagonist. Sulpiride appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or gamma-aminobutyric acid (GABA) receptors.[7]
Pharmacodynamics
Sulpiride is a substituted benzamide derivative and a selective dopamine D2 antagonist with antipsychotic and antidepressant activity. Other benzamide derivatives include metoclopramide, tiapride, and sultopride.[7]
References
- ^ Generon. "Levosulpiride - S-(-)-Sulpiride - >98% Generon". www.generon.co.uk. Retrieved 2016-08-31.
- ^ a b http://www.stratech.co.uk/. "Levosulpiride | Stratech Scientific Ltd". www.stratech.co.uk. Retrieved 2016-08-31.
{{cite web}}
: External link in
(help)|last=
- ^ Poluzzi, Elisabetta; Raschi, Emanuel; Koci, Ariola; Moretti, Ugo; Spina, Edoardo; Behr, Elijah R.; Sturkenboom, Miriam; Ponti, Fabrizio De (2013-04-04). "Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database". Drug Safety. 36 (6): 467–479. doi:10.1007/s40264-013-0032-z. ISSN 0114-5916. PMC 3664739. PMID 23553446.
- ^ http://www.drugsupdate.com/generic/view/860
- ^ Poluzzi, Elisabetta; Raschi, Emanuel; Koci, Ariola; Moretti, Ugo; Spina, Edoardo; Behr, Elijah R.; Sturkenboom, Miriam; Ponti, Fabrizio De (2013-04-04). "Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database". Drug Safety. 36 (6): 467–479. doi:10.1007/s40264-013-0032-z. ISSN 0114-5916. PMC 3664739. PMID 23553446.
- ^ "Rapid onset resistant dystonia with low dose of Levosulpiride". 2016-08-24.
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ a b "Sulpiride". Drugbank.ca. DB00391.